Investors in Guardant Health (NASDAQ:GH) From Three Years Ago Are Still Down 86%, Even After 8.3% Gain This Past Week
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while. So take a moment to sympathize with the long term shareholders of Guardant Healt
Simply Wall StMay 3 08:48 ET
Guardant Health Is Maintained at Buy by Canaccord Genuity
Guardant Health Is Maintained at Buy by Canaccord Genuity
Dow JonesApr 29 10:48 ET
Canaccord Genuity Maintains Buy on Guardant Health, Lowers Price Target to $30
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $45 to $30.
BenzingaApr 29 10:37 ET
Express News | Guardant Health Inc : Canaccord Genuity Cuts Target Price to $30 From $45
ReutersApr 29 01:20 ET
Guardant Health Coverage Assumed by Craig-Hallum at Buy
Guardant Health Coverage Assumed by Craig-Hallum at Buy
Dow JonesApr 24 13:44 ET
Express News | Craig-Hallum Assumes Guardant Health at Buy, Announces Price Target of $28
Moomoo 24/7Apr 24 13:34 ET
Express News | Guardant Health, Inc. : Craig-Hallum Cuts Target Price to $28 From $54
Moomoo 24/7Apr 24 07:06 ET
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Health care stocks rose Monday afternoon with both the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 1%. The iShares Biotechnology ETF (IBB) climbed 1.7%. In cor
MT NewswiresApr 22 13:55 ET
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Matterport, Inc. (NASDAQ:MTTR) rose sharply during Monday's session.CoStar Group, Inc. (NASDAQ:CSGP) anno
BenzingaApr 22 10:10 ET
Express News | FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Moomoo 24/7Apr 22 08:52 ET
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will
BusinesswireApr 18 16:05 ET
Guardant Health Is Maintained at Buy by Goldman Sachs
Guardant Health Is Maintained at Buy by Goldman Sachs
Dow JonesApr 15 10:36 ET
Express News | Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $28
Moomoo 24/7Apr 15 10:25 ET
Express News | Guardant Health Inc : Leerink Partners Cuts Target Price to $40 From $50
Moomoo 24/7Apr 12 08:01 ET
Analyst Expectations For Guardant Health's Future
During the last three months, 5 analysts shared their evaluations of Guardant Health (NASDAQ:GH), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent ratin
BenzingaApr 5 11:00 ET
Express News | Guggenheim Reiterates Neutral on Guardant Health
Moomoo 24/7Apr 5 10:06 ET
Guardant Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 — Guggenheim Reiterates → Neutral 02/26/2024 64.35% Piper Sandler $40 → $30 Maintains Overweig
BenzingaApr 5 10:04 ET
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of Guardant Reveal in
BusinesswireApr 3 08:05 ET
20 Foods To Reduce Cancer Risk
Yahoo FinanceMar 30 19:43 ET
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 47% Undervaluation?
Key Insights Guardant Health's estimated fair value is US$39.28 based on 2 Stage Free Cash Flow to Equity Guardant Health's US$20.63 share price signals that it might be 47% undervalued Analyst p
Simply Wall StMar 29 07:03 ET
No Data
No Data